Conv. Plasma
Nigella Sativa

Home COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Azadirachta indica for COVID-19

Azadirachta indica has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Patil et al., Targeting multiple SARS-CoV-2 domains by Indian medicinal plants – A Drug repurposing study using molecular docking, ADME-Tox analysis, Research Square, doi:10.21203/
Abstract The rapid transmission of SARS-CoV-2 and its capability to spread in humans has brought about the development of new approaches for treatment against COVID-19. Drugs and vaccines available currently either target the virus ectodomain or endodomain. Thus, repurposing the use of natural products that target more than one part of the virus is the fastest option available for treatment. Plants are a repository of important constituents with proven significant efficacy against many human viruses. The present study focused on employing computational approaches for screening phytochemicals from 4 Indian medicinal plants, by targeting more than one part of SARS-CoV-2 for the identification of natural antiviral therapeutics to determine their feasibility as potential inhibitors of target viral proteins. Here, we used a multi-target, ligand virtual screening study on 9 target proteins important in SARS-CoV-2 lifecycle, namely Spike glycoprotein, Nucleocapsid phosphatase, Spike protein ACE-2, Non-structural protein 10 and 12, RdRp, Envelope protein, Main protease/3CL protease, and Papain like proteas. Out of the 58 plant phytochemicals screened, Z-5-methyl-6- heneicosen-11- one from Piper nigrum, Arjunetin from Terminalia arjuna, Rutin from Azadirachta indica and Makisterone A from Tinospora cordifolia exhibited highest binding affinity with 9 viral targets. In addition, ADMET analysis indicated Ursodeoxycholic acid, Ellagic Acid, Epicatechin and Isocolumbin, Ecdysterone, Columbin from Piper nigrum, Terminalia arjuna, Azadirachta indica, and Tinospora cordifolia have good binding energetics with the target viral proteins. The research thus enlightens the suitable pharmacological properties and the anti-viral activity of potential medicinal plant molecules for human administration using extensive in-silico techniques.
Dofuor et al., The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions, Clinical Pathology, doi:10.1177/2632010x231218075
In December 2019, an outbreak of a respiratory disease called the coronavirus disease 2019 (COVID-19) caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China. The SARS-CoV-2, an encapsulated positive-stranded RNA virus, spread worldwide with disastrous consequences for people’s health, economies, and quality of life. The disease has had far-reaching impacts on society, including economic disruption, school closures, and increased stress and anxiety. It has also highlighted disparities in healthcare access and outcomes, with marginalized communities disproportionately affected by the SARS-CoV-2. The symptoms of COVID-19 range from mild to severe. There is presently no effective cure. Nevertheless, significant progress has been made in developing COVID-19 vaccine for different therapeutic targets. For instance, scientists developed multifold vaccine candidates shortly after the COVID-19 outbreak after Pfizer and AstraZeneca discovered the initial COVID-19 vaccines. These vaccines reduce disease spread, severity, and mortality. The addition of rapid diagnostics to microscopy for COVID-19 diagnosis has proven crucial. Our review provides a thorough overview of the historical development of COVID-19 and molecular and biochemical characterization of the SARS-CoV-2. We highlight the potential contributions from insect and plant sources as anti-SARS-CoV-2 and present directions for future research.
Khaledi et al., A Comprehensive Review of Herbal Recommendations with the Potential to Inhibit COVID-19 Infection, Journal of Medical Bacteriology, doi:10.18502/jmb.v11i5-6.14362
Background: The outbreak of Coronavirus Disease 2019 (COVID-19) has originated from Wuhan, China and rapidly spread all over the world. This disease is caused by a coronavirus termed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that mainly infects the human respiratory tract. Herbal agents including Atractylodes lancea, Ephedra, Curcumin, and Echinacea purpurea had immunomodulatory effects and antiviral activities on other respiratory viruses including Influenza virus. They strengthen the innate immunity through increasing the phagocytic activity and antiinflammatory activity. These herbs could be used as a complementary therapy to prevent entry of COVID-19 and improve immune system. This review delves into the role and therapeutic compounds of various herbal agents in relation to immunity, their effectiveness in treating other viral respiratory illnesses, and their potential influence on COVID-19 disease.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.